AstraZeneca pulls out of bid to hold Covid-19 vaccine trials in Philippines; virus cases almost reaching 450,000 thestar.com.my - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thestar.com.my Daily Mail and Mail on Sunday newspapers.
Adjust font size:
MANILA, Dec. 11 (Xinhua) AstraZeneca, the Britain-based drug maker, has withdrawn its application to conduct COVID-19 vaccine clinical trials in the Philippines, the country s Food and Drug Administration (FDA) said on Friday. They (AstraZeneca) said they have enough data already, Enrique Domingo, the FDA director general, said in a text message to Xinhua, explaining the reason AstraZeneca cited for withdrawing trials application.
AstraZeneca last month applied to conduct the coronavirus vaccine clinical trials in the philippines, and it had already passed the ethics board when it decided to withdraw.
AstraZeneca can still supply the country with coronavirus vaccines without holding trials in the Philippines, Domingo said.
2020-12-11 12:36:10 GMT2020-12-11 20:36:10(Beijing Time) Xinhua English
MANILA, Dec. 11 (Xinhua) AstraZeneca, the Britain-based drug maker, has withdrawn its application to conduct COVID-19 vaccine clinical trials in the Philippines, the country s Food and Drug Administration (FDA) said on Friday. They (AstraZeneca) said they have enough data already, Enrique Domingo, the FDA director general, said in a text message to Xinhua, explaining the reason AstraZeneca cited for withdrawing trials application.
AstraZeneca last month applied to conduct the coronavirus vaccine clinical trials in the philippines, and it had already passed the ethics board when it decided to withdraw.
AstraZeneca can still supply the country with coronavirus vaccines without holding trials in the Philippines, Domingo said.
AstraZeneca pulls out of bid to hold COVID-19 vaccine trials in Philippines - Xinhua xinhuanet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from xinhuanet.com Daily Mail and Mail on Sunday newspapers.